Bayer Nubeqa Patient nmCRPC Brochure

CHOOSING NUBEQA

NUBEQA IS CLINICALLY PROVEN

NUBEQA HAS BEEN PROVEN TO WORK IN THE LARGEST CLINICAL TRIAL OF ITS KIND NUBEQA was studied in a clinical trial with more than 1500 men with nmCRPC. In this study, 955 men added NUBEQA to their hormone therapy* and 554 received hormone therapy alone. This study measured the length of time living without the cancer spreading to other parts of the body, also called metastasis-free survival (MFS) . The study also measured overall survival (OS) , which is how long a person may live after starting therapy.

ADDING NUBEQA HELPED KEEP nmCRPC IN ITS PLACE

without their prostate cancer spreading to other parts of the body when they added NUBEQA to hormone therapy vs hormone therapy alone

(median † 3.4 years vs 1.5 years) 2X LONGER MEN LIVED

In a clinical trial

NUBEQA HELPS YOU LIVE FOR WHAT YOU LOVE

*Hormone therapy includes drug treatments or surgery that lowers testosterone. † Median is the middle value in a set of numbers, not the average.

31 % LOWER RISK OF DEATH

NUBEQA MAY ALSO HELP YOU LIVE LONGER The study also showed that NUBEQA significantly extended OS compared with hormone therapy*alone. • NUBEQA extended OS by lowering the risk of death by 31% compared with hormone therapy alone

IMPORTANT SAFETY INFORMATION (continued) Before taking NUBEQA, tell your healthcare provider about all your medical conditions, including if you (continued): • have a partner who may become pregnant. Males who have female partners who may become pregnant should use effective birth control (contraception) during treatment and for 1 week after the last dose of NUBEQA. Talk with your healthcare provider about birth control methods • are breastfeeding or plan to breastfeed. It is not known if NUBEQA passes into breast milk

*Hormone therapy includes drug treatments or surgery that lowers testosterone.

Please see additional Important Safety Information throughout and the full Prescribing Information.

9

Made with FlippingBook flipbook maker